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Microbicidal activitycal and extremely rare case of X-linked CGD in an Italian family characterized by a
low expression of gp91phox (X91− CGD). A novel point mutation in the CYBB gene's promoter (insertion of a T
at position −54T to −56T) appeared to prevent the full expression of this gene in the patient's neutrophils and
correlated with a residual oxidase activity in the whole cells population. The expression and functional
activity of the oxidase in eosinophils appeared to be almost normal. Gel shift assays indicated that the
mutation led to decreased interactions with DNA-binding proteins. The total O2− production in the patient's
granulocytes (5–7% of normal) supported no microbicidal power after 45 min and 60 min of contact with S.
aureus and C. albicans, respectively. Despite this residual oxidase activity, the patients suffered from severe
and life-threatening infections. It was concluded that in these X91− CGD neutrophils, the O2− production per se
was not sufﬁcient to protect the patient against severe infections.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionChronic granulomatous disease (CGD) is a rare congenital
immunodeﬁciency syndrome clinically characterized by severe recur-
rent bacterial and fungal infections, which are relatively resistant to
treatment, by conventional means [1,2]. The majority of the patients
are now diagnosed before their second birthday, although some may
remain undiagnosed until later childhood or even adult life [3,4]. CGD
is due to a defect in the NADPH oxidase system of phagocytes [2]. This
enzymatic complex is composed of a membrane-bound ﬂavocyto-
chrome b558, the redox center of the oxidase, and three cytosolic
components: p47phox, p67phox and p40phox. Two small G proteins,
rac2 and rap1A/B, are also involved in regulating NADPH oxidase
activity. Cytochrome b558, the terminal redox membranous compo-
nent of the phagocyte NADPH oxidase, is a heterodimer composed of
an α subunit, the small p22phox, and a β subunit, the heavy chain
gp91phox or Nox2. Gp91phox is the ﬂavinoxidase element capable of
transferring electrons, while p22phox stabilizes the expression of this
component [5]. The incidence of CGD is about 1 in 250,000rier, Faculté de Médecine; the
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l rights reserved.individuals. On the basis of the mode of inheritance, two forms of
the disease are know: an autosomal form with mutations in CYBA,
NCF1 and NCF2 genes encoding p22phox, p47phox and p67phox
proteins, respectively, and an X-linked form with mutations in the
CYBB gene encoding gp91phox, which accounts for more than 60% of
CGD cases [6,7]. CYBB gene encompasses 13 exons spanning about
30 kb of human X chromosome genomic DNA [8,9]. In the so-called
classical form of CGD which includes the majority of X-linked cases,
cytochrome b558 is absent and there is no detectable oxidase activity
(X910). A number of cases with “variant” forms of the disease, called
X91− CGD have also been described, inwhich low levels of cytochrome
b558 expression are accompanied by a proportionally decreased
NADPH oxidase activity [10]. Mutations associated with this pheno-
type are usually located in the coding region (exons) of CYBB [11–16].
These variants are of interest because they cause a structural
disorganization leading either to an incomplete loss of protein or to
a partial dysfunction, or both. Mutations in the upstream promoter
region of CYBB leading to the X91− CGD phenotype have also been
described. To our knowledge only four point mutations were reported
in this region (C-52T, C-53T, T-55C and A-57C) [17–19]. These
mutations are located between the “CCAAT” and the “TATA” boxes in
a consensus binding site for the ets family of transcription factors of
the gp91phox promoter responsible for CYBB transcription [17].
Despite the low expression of gp91phox protein and the residual
NADPH oxidase activity in phagocytes, the clinical appearance of these
speciﬁc X91− CGD patients varies considerably frommild forms [18] to
severe clinical phenotypes with multiple life-threatening infections
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and other derived reactive oxygen species (ROS) by activated
phagocytic cells are critical for effective protection against infections.
A striking point is that in most of the X91− CGD cases characterized by
a mutation in the CYBB promoter, the CGD diagnosis is made in
adolescents (N10 years) or in adults.
We report a novel point mutation in the CYBB gene promoter
(insertion of a T at position −54/−56) leading to a rare X91− CGD case
in an Italian family with two members affected by CGD. The mutation
caused a reduced expression of gp91phox at the mRNA and protein
levels associated with a decreased ability to generate O2− and H2O2
(∼7% of control neutrophils). A decrease in the binding of nuclear
factors to the mutated promoter region was found in electrophoretic
mobility shift assays. However, the patient's eosinophils were NBT-
positive, displayed DHR oxidation and were gp91phox-positive.
Despite a weak respiratory burst activity, the patient's granulocytes
did not kill either S. aureus or C. albicans even with long incubation
times. The CGD diagnosis for both patients was made in adulthood.
One of them died from a bilateral pneumonia while the other suffers
from sporadic respiratory and skin infections that are kept under
control by conventional antibiotic therapy. These observations raise
questions about the role and the levels of ROS needed for protection
against bacterial and fungal infections.
2. Materials and methods
2.1. Materials
Phorbol 12-myristate 13-acetate (PMA) and cytochrome c (type VI,
from horse heart) were from Sigma Chemical Co. (St. Louis, MO).
Percoll, reagents and molecular weight markers for SDS-PAGE were
obtained from Amersham Pharmacia Biotech (Little Chalfont, Buck-
inghamshire, UK). Nitrocellulose sheets for Western blotting were
purchased from Bio-Rad Laboratories. Monoclonal antibodies (MAbs)
449 and 48 were provided by D. Roos and A.J. Verhoeven. Mab 7D5
was provided by Clinisciences (Montrouge, France). Control IgG1 mAb
from amousemyelomawas purchased from Sigma Chemical Co. Alexa
Fluor 647 rat anti-human CD294 (CRTH2) was purchased from BD
Biosciences (San Jose, CA, USA).
2.2. Cases report of patients II-2 and III-5 of family C (Fig. 1)
Patient II-2 was born in 1947. His mother died several years ago
from undeﬁned pathology while his father passed away recently. His
son (III-1) is in good health and his daughters (III-2, III-3) are carriers
of the disease. The patient sisters are both CGD carriers and one of
them died recently. The brother died of pneumonia at the age of 14.
Diagnosis of CGD was made in 1991 immediately after his nephew
(patient III-5) was diagnosed as having CGD at the age of twenty
during the terminal phase of the disease. Patient II-2 was relatively
well until he was 5 years old. He subsequently had a history of skin
abscesses, pulmonary infections with pleuritis treated with antibiotic
therapy. The clinical history of patient II-2 is characterized by episodes
of bronco-pneumonia, skin ulcero-necrotic lesions and an otitis media
with tympanic membrane perforation, which responded to antibiotic
treatment. At present the patient is in a relatively good health and
does not receive antibiotic proﬁlaxis.
Patient III-5, who is the nephew of patient II-2, was born in 1970
and died in 1990. He had no complaints and was healthy until the age
of 19. In 1989 he developed severe multiple site infection of the skin
with necrotic granuloma with involvement of the right latero cervical
nodes and of the lung with pleural effusion sepsis that required
hospitalization. Serratia marcescens was isolated from the blood and
the lymph node. Lymph node and pleural lesions required surgical
drainage. On that occasion, a marked defect in the respiratory burst of
granulocytes was detected by a luminol-dependent chemilumines-cence assay using opsonized zymosan as stimulating agent. Anti-
biotics including ceftazidime and netilmicin were administered and
the patient recovered in ﬁve weeks. Hewas admitted again to hospital
six months later, in March 1990, with fever, cough, dyspnoea and
radiological evidence of a bilateral pneumonia. After a few days from
admission the general conditions of the patient worsened and
intensive care unit assistance was required. Two blood cultures were
positive for Staphylococcus sp. (non aureus). Pseudomonas aeruginosa
and Candida albicans were isolated from bronchial brushings.
Antibiotic treatment, including ceftazimide, piperacilline, netilmicine
and teicoplanine failed to control fever and pulmonary infection. After
diagnosis was made, and before the molecular nature of the defect
was known, it was hypothesized that the low activity of NADPH
oxidase could be the result of enzyme instability. Accordingly, it was
thought that “younger” cells could possess higher oxidase activity and
kill microorganisms more efﬁciently. Therefore, GM-CSF was used
with the aim of accelerating neutrophil release from the bone marrow
and exploiting its known ability to prime neutrophils for enhanced
response to agonists [20].
Human recombinant GM-CSF (kindly provided by Schering-
Plough) was given, beginning with a dose of 5 μg/kg/die escalating
to a maximum of 10 μg/kg/die and then modulating the dose in order
to maintain WBC count below 10×109/l. GM-CSF was given sub-
cutaneously at 12 h intervals. Treatment with GM-CSF lasted for
22 days and led to a fast and sustained increase of the WBC and
neutrophil count, without detectable effects on haemoglobin con-
centration and platelet count, and without side effects. However, in
spite of the marked increase in the neutrophil count, there was no
change in the percentage of NBT-positive cells and in the amount of
superoxide anion produced after PMA stimulation (data not shown).
After a slight and temporary clinical improvement, the patient's
conditionsworsened, with high fever, unconsciousness and increasing
dyspnoea, which required mechanically assisted ventilation. Left
pneumo-thorax developed and death occurred 38 days after admis-
sion. During the late course of the disease Pseudomonas and Staphy-
lococcus were again isolated from bronchial brushings and from the
blood, respectively.
2.3. Isolation of polymorphonuclear and mononuclear leucocytes
Human neutrophils were isolated from citrated blood samples of
patients, their parents and healthy donors after their informed
consent, by sequential dextran sedimentation and Ficoll-Hypaque
differential density centrifugation, followed by erythrocyte lysis by
hypotonic treatment, as described elsewhere [21]. The isolated
neutrophils were resuspended in Ca2+ and Mg2+ free HEPES-buffered
saline (HBS) solution containing 140 mM NaCl, 5 mM KCl, 5 mM
Glucose, 5 mM HEPES, pH 7.4 and 0.2% bovine serum albumin (BSA).
Immediately before use, cell suspensions were supplemented with
1 mM CaCl2 and 1 mM MgCl2. Isolated mononuclear cells were
transformed with the B95-8 strain of Epstein Barr virus (EBV) and
were grown in RPMI-1640 supplemented with 10% fetal calf serum,
100 U/ml penicillin, 50 μg/ml streptomycin, at 37 °C in a 5% CO2
atmosphere [22].
2.4. Assay of superoxide anion production
Superoxide anion was measured spectrophotometrically by the
superoxide dismutase-inhibitable cytochrome c reduction at 550 nm,
as previously described [19,23].
2.5. Assay of hydrogen peroxide production
Hydrogen peroxide was measured by the dihydrorhodamine-1,2,3
(DHR) assay. In this assay, the nonﬂuorescent DHR is converted by
hydrogen peroxide to the green ﬂuorescent rhodamine 123 and
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2 μM DHR 123 (Molecular Probes, Eugene, UR, USA) at room
temperature for 30 min, in the dark. After loading and addition of
1 mM sodium azide, the samples were prewarmed at 37 °C in a
shaking water bath and after 10 min the cells were stimulated with
20 ng/ml phorbol-myristate acetate (PMA) for 15 min; the reaction
was stopped by dilution with ice cold PBS. Samples were kept on ice
and cell-associated ﬂuorescence (FL-1) was measured by ﬂow
cytometry (FACScalibur™, BD Biosciences, San Jose, CA). In experi-
ments where expression of the eosinophil marker CRTH2 was also
measured, the samples were further incubated with 2.5 μg/ml Alexa
Fluor 647 rat anti-human CD294 (CRTH2) for 30 min and washed
twice with cold HBS-BSA, before cytometry readings.
2.6. NBT test
Neutrophils were suspended at 0.2×106/ml in HBS-BSA containing
1 mM EDTA to prevent cell aggregation and 1 mM NBT. The reaction
was started by addition of 100 ng/ml PMA. After incubation for 15 min
at 37 °C cytospins were made, ﬁxed with methanol and counter-
stained with a solution of 0.4% safranin in 25% ethanol. In some
experiments the NADPH oxidase inhibitor diphenyleneiodonium (DPI)
(f.c. 5 μM) was included in the incubation mixture.
2.7. Cytochrome b558 spectroscopy
Reduced minus oxidized optical spectra of cytochrome b558 were
recorded at room temperature on aDU640Beckman spectrophotometer,
after addition of a few crystals of sodium dithionite, as previously
reported [24]. Amolar extinction coefﬁcient ɛ426–410 nm=200mM−1 cm−1
for the Soret band was used for calculations.
2.8. Expression of gp91phox in neutrophils and eosinophils as measured
by ﬂow cytometry
Granulocytes (106 cells) were suspended in 0.1 mL HBS-BSA and
incubated with 5 μg/ml of mab 7D5 (anti-gp91phox) [25] or control
isotype-matched (IgG1) mab for 30 min on ice. The cells were washed
twice and incubated with Alexa Fluor 488 goat-F(ab)2 anti-mouse
IgG1 (Invitrogen, Cergy Pontoise, France) for 30 min on ice. After two
washes as above, the cells were incubated with 2.5 μg/ml Alexa Fluor
647 rat anti-human CD294 (CRTH2) for 30 min on ice and washed
[26,27]. Cell-associated ﬂuorescence (FL1 and FL4) was measured on
100,000 events.
2.9. Assay of microbicidal activity
The microbicidal activity was tested according to a recently
described method [28]. Brieﬂy, neutrophils (ﬁnal concentration:
4×106/ml) were incubated at 37 °C with serum-opsonized Staphylo-
coccus aureus (strain 502 A, ATCC 27217), Escherichia coli (ATCC 25922,
a serum-resistant strain) or a clinical isolate of Candida albicans at a
microorganism/neutrophil ratio of 3:1 for bacteria and 2:1 for the
fungus, in HBS-BSA containing 1mMCaCl2 andMgCl2. At the indicated
times of incubation aliquots were diluted 50 times inwater brought to
pH 11.0 with 1 M NaOH. After 5 min at room temperature samples
were vortexed, diluted in 0.9% NaCl solution and plated on Petri
dishes. After overnight incubation, colony forming units (CFU) were
counted and the percentage of killing was calculated with respect to
the number of CFU at time 0 of incubation.
2.10. SDS-PAGE and immunoblotting
Neutrophil proteins were solubilised in 1% Triton X-100, separated
by SDS-PAGE in 10% (w/v) acrylamide gel with a 5% (w/v) stacking gel
[29], electrotransferred to nitrocellulose [30] and immunodetectedusing the monoclonal antibodies 449 and 48 directed against p22phox
and gp91phox, respectively [31] and by polyclonal antibodies directed
against p47phox and p67phox [32].
2.11. Electrophoretic mobility shift assays (EMSA)
2.11.1. Nuclear extracts
Nuclearextracts of undifferentiatedPLB-985 cellswerepreparedwith
the NE-PER nuclear extraction reagents of the Pierce kit (Thermo Fisher
Scientiﬁc Inc., Waltham, USA) according to the manufacturer's instruc-
tions and stored at −80 °C. The protein concentration was determined
with the BioRad protein assay kit (Biorad, Marnes-La-Coquette, France).
2.11.2. Oligonucleotides
Oligonucleotides used as double-stranded competitors and probes
are as follows: WT CYBB [−68 to −30] bp (WT, 5′-ctatgcttcttcttcc-
aatgaggaaatgaaaacagcag-3′); X91− mutated CYBB (X91− CGD, 5′-ctatg-
cttcttcttccaatgaggaaaatgaaaacagcag-3′). Oligonucleotide probes were
labelled by biotin according to Biotin 3′ End DNA Pierce Labelling Kit
(Thermo Fisher Scientiﬁc Inc.), followed by annealing with the
complementary strand oligonucleotides.
Electrophoretic mobility shift assays were performed in a 20-μL
total volume with 10 μg of nuclear protein extract in 10 mM Tris,
50 mM KCl, 1 mM DTT (pH 7.5), 50 ng/μL Poly (dI–dC). Nuclear
extracts were preincubated for 15 min on ice with or without a 20-,
50-, or 100-fold molar excess of unlabelled double-stranded
oligonucleotide competitors followed by an additional 30 min on
ice after the addition of 1 nM of biotin-labelled double-stranded
oligonucleotides. Samples were subjected to a 5% polyacrylamide gel
electrophoresis at 100 V for 2 h in a 0.5× Tris-Borate-EDTA buffer (pH
8.3) and transferred to a nylon membrane Hybond™–N+ (Amersham,
GE Healthcare, Munich, Germany). After transfer the membrane was
immediately cross-linked for 45–60 s at 120 mJ/cm2 using an UV-
light cross-linker instrument equipped with 254-nm bulbs. The
biotin-labelled DNA was detected by chemiluminescence using a
luminol/enhancer solution and a stable peroxide solution (Pierce
labelling kit). Membranes were exposed to an X-ray ﬁlm for 15 min
before developing.
2.12. Preparation of RNA and DNA
Total RNA was isolated from either mononuclear cells or EBV-
transformed B lymphocytes, using a modiﬁed single-step method
[33,34]. Genomic DNA was puriﬁed following classic procedures
Genomic DNA was also puriﬁed from the peripheral blood of patient
II-2 and healthy donor according to the manufacturer's instructions
(Wizard kit, Promega, France).
2.13. cDNA ampliﬁcation and sequencing
First-strand cDNA was synthesized from 5 μg of total RNA from
Epstein Barr virus immortalized B lymphocytes or native B lympho-
cytes or granulocytes by reverse transcriptase (RT) reaction according
to the manufacturer's instructions (QBiogene, Illkirch, France). Total
gp91phox cDNA was immediately ampliﬁed by PCR in three over-
lapping fragments [35]. Aliquots of 10 μL PCR products in bromophe-
nol blue solution were run together with a scale of DNA ladders
(markers VI, Roche Diagnostics, Indianapolis, IN, USA) on 1.5% (wt/vol)
agarose or on 5% acrylamide gels containing 1 μg/ml ethidium
bromide. The bands were photographed under UV (Vilber Lourmat,
Biolabo Scientiﬁc Instruments, Archamps, France). In some cases PCR
products were puriﬁed from agarose gel with the Sephaglas kit
(Amersham Pharmacia, Orsay, France). All RT-PCR products were
sequenced by Cogenics (Meylan, France) using the Abi Prism
automatic sequencer (Perkin Elmer, Foster City, CA, USA). For each
patient, the complete encoding region of CYBB was sequenced.
Table 1
Superoxide anion (O2−) production, NBT reduction, and cytochrome b558 content of
neutrophils from family C members and the members of a family with a CGD patient











II-1 226.0 100 strong NT
II-2 13.2 100 weak to negative 20.0
II-3 68.1 52 strong 48 weak to negative NT
II-4 83.3 53 strong 47 weak to negative NT
III-1 217.3 100 strong NT
III-2 118.9 64 strong 36 weak to negative NT
III-3 91.3 53 strong 47 weak to negative NT
III-4 19.8 56 strong 44 weak to negative 72.5
III-5 8.9±1.8 (3) 100 weak to negative 14.8±4.3 (3)
Healthy donor 197.9±7.1 (3) 100 strong 166.0
Family of patient
with X910 CGD
Father 181.9 100 strong 100.7
Mother 99.2 61 strong 39 negative 62.5
Son b0.5 100 negative b5
For experimental details see Materials and methods. In parenthesis is the number of
experiments.
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Semi-quantitative PCR was performed to evaluate CYBB gene
expression in mononuclear cells or granulocytes. Two microliters of
cDNA (obtained as described before) was used in 100 μL of total
reaction mixture containing 10 μL of 10× Qbiogen incubation mix
supplemented with 0.2 mM Mg++, 0.25 μM dNTP, speciﬁc primers 1
and 2⁎ (see primer sequence in Table 2), 0.25 μM β-actin primers (3
and 4⁎) and 25 mU/μL Taq DNA polymerase (QBiogene, Illkirch,
France). The reaction mixture was thermally cycled in a Minicycler™
(MJResearch, St Bruno, Canada) once at 95 °C for 5 min, 25 times at
95 °C for 1min, 57 °C for 1min, 72 °C for 90 s and then once at 72 °C for
7 min. Aliquots of 10-μL PCR products in bromophenol blue solution
were run together with a scale of DNA ladders (marker XIV, Roche,
Meylan, France) on 1.5% (wt/vol) agarose gels containing 1 μg/ml
ethidium bromide and visualized on a UV transilluminator.
2.15. Genomic DNA ampliﬁcation
Puriﬁed genomic DNA was ampliﬁed using a forward primer P1
CAGCAAGGCTATGAATGCTGTTC (position −427 in the CYBB promoter
region and the backward one P2⁎ GGAGAGCCCCTCATTCACAG (posi-
tion +45). PCR products were automatically sequenced by Cogenics
(Meylan, France) using the Abi Prism automatic sequencer (Perkin
Elmer, Courtaboeuf, France) with forward and backward primers [19].
2.16. Protein determination
Protein content was measured by using the PierceR method [36].
3. Results
Fig. 1 shows the pedigree of Family C studied in this paper. Patient
II-2 was diagnosed with CGD immediately after his nephew (patient
III-5) was diagnosed as having CGD at the age of 20 on the basis NBT
test, PMA-induced superoxide production and cytochrome b content
(Table 1). Patient II-2 was 43 at the time of diagnosis and his
neutrophils in terms of respiratory burst activity (NBT and superoxide
production) and cytochrome b content had characteristics similar to
neutrophils of patient III-5 (Table 1). Production of superoxide anion
by neutrophils from patients II-2 and III-5 after PMA stimulationwas 7
and 5% of control cells, respectively (Table 1). Neutrophils from family
members II-3, II-4, III-2, III-3 and III-4 generated intermediate
amounts of superoxide ranging from 34% to 60% of control (Table 1).
These data are compatiblewith an X-linkedmode of inheritance of the
defect. This conclusion was conﬁrmed by the results of the NBT test
that showed that neutrophils from II-3, II-4, III-2, III-3 and III-4 were a
mosaic in terms of NBT reduction, with two populations, one stronglyFig. 1. Pedigree of family C. Individuals II-3, II-4, III-2, III-3, III-4 were proven to be carriers f
contrast, individuals II-1 and III-1 were normal in terms of NBT reduction and superoxide
affected male; (†), deceased; NT, not tested.positive, and the other negative while neutrophils from II-1 and III-1
were 100% NBT positive. In patients II-2 and III-5 a few cells were
weakly NBT positive (Fig. 2 arrows and arrowheads). Such NBT
positive cells were no longer apparent when DPI was included in the
incubation mixture. Among the NBT positive cells, the more weakly
positive (arrows) appeared to be neutrophils while the more strongly
positive (arrowheads), based on the nuclear shape, the size and color
of intracellular granules could be identiﬁed as eosinophils. The
percentage of eosinophils as determined in Diff-Quick stained smears
in patients II-2 and III-5 never exceeded 3% (data not shown).
To better establish if neutrophils from patient II-2 exhibited a
NADPH oxidase activity, we measured the respiratory burst using a
methodmuchmore sensitive than the NBT reduction test, i.e. the DHR
oxidation assay. Fig. 3 shows that neutrophils from patient II-2
presented a homogeneous cell population with a peak response
corresponding to about 5% of control. Such a response was almost
completely abolished by DPI. No response was observed with
neutrophils from an X910 CGD patient. In order to establish whether
a population of NADPH oxidase-positive eosinophils, as indicated by
the NBT reduction test, was detectable using the DHR assay in the
granulocytes of patient II-2, we conducted an experiment in which
eosinophils were identiﬁed with an anti-CRTH2 mAb and with
acquisition of a number of events (100,000) larger than that used in
Fig. 3 (10,000). Fig. 4 shows that, indeed, a small percentage of
DHR and CRTH2-positive cells (eosinophils) were present in theor X-linked CGD on the basis of NBT reduction and superoxide production (Table 1). In
production (Table 1). (□), normal male; (○), normal female; ( ), carrier female; (■),
Fig. 2. NBT test in neutrophils from the patient II-2. Puriﬁed neutrophils from patient II-2 or a healthy donor were pre-incubated or not with 5 μMDPI and stimulated with 20 ng/ml
PMA in the presence of 1 mM NBT for 15 min at 37 °C. Arrows indicate neutrophils weakly NBT positive; arrowheads indicate eosinophils more strongly NBT positive.
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of cytochrome b558 in the patients' neutrophils, reduced minus
oxidized difference spectra of neutrophil homogenates and Western
blot analysis were performed. As illustrated in Fig. 5A and Table 1,
reduced-minus-oxidized spectra revealed a low but detectable
amount of cytochrome b558. The spectrum of X910 CGD neutrophils
did not present the peaks characteristic of cytochrome b558.
Cytochrome b558 content in patients II-2 and III-5 was 14 and 10% of
normal neutrophils, respectively, while the neutrophils of a hetero-
zygous member of family C (patient III-4) contained 44% of control
cytochrome b558 (Table 1).
The presence of low amounts of cytochrome b558 in neutrophils of
these patients was conﬁrmed by Western blot analysis using an
identical amount of 1% Triton X-100 soluble extract in all samples
(50 μg). Fig. 5B shows that in comparison with normal cells, the two
bands corresponding to gp91phox and p22phox were very faint. The
speciﬁcity of the bands detected by the use of monoclonal antibodiesFig. 3. Flow cytometric histograms of hydrogen peroxide generation from X CGD patients. D
patient II-2 and a X910 CGD patient were incubated for 15 min at 37 °C without (resting) or
methods, and analyzed by ﬂow cytometry.directed against the two subunits of cytochrome b558 was conﬁrmed
by the absence of gp91phox and p22phox in the extracts from
neutrophils of an X910 CGD patient. The cytosolic components of
NADPH oxidase (p47phox, p67phox, p40phox and Rac2) detected by
Western blot analysis were normal (data not shown). Since the
spectroscopic and Western blot analyses do not distinguish eosino-
phils from neutrophils and since in the NBT slide test eosinophils
appeared to stain more strongly than neutrophils (Fig. 2), a ﬂow
cytometry experiment was devised that would distinguish gp91phox
expression in neutrophils and eosinophils. Fig. 6 shows the dot plot
proﬁles of granulocytes from a normal subject (top panels) and from
patient II-2 (bottom panels) incubated simultaneously with the anti-
eosinophil mab CRTH2 and with the anti-gp91phox 7D5 mab
antibodies (gp91phox) or an isotype-matched nonspeciﬁc mAb
(control mAb). The percentage of eosinophils in the two cell
preparations was 0.9 for the normal subject and 2.5 for patient II-2.
The right panels show that both neutrophils (99.0%) and eosinophilsihydrorhodamine-1,2,3 (DHR)-loaded neutrophils (106 cells/ml) from a healthy donor,
with 20 ng/ml PMA or PMA in the presence of 5 μM DPI, as described in Materials and
Fig. 4. Flow cytometric dot plots of hydrogen peroxide generation from neutrophils and eosinophils in granulocyte preparations from a healthy subject (top panels) and patient II-2
(bottom panels) at rest (left panels) or after stimulation with PMA (right panels). Dihydrorhodamine-1,2,3 (DHR)-loaded granulocytes (106 cells/ml) were incubated for 15 min at
37 °C without or with 20 ng/ml PMA. After dilution with ice-cold PBS the cells were incubated with Alexa Fluor 647 rat anti-human CD294 (CRTH2) for 30 min and washed, before
cytometry readings, as described in Materials and methods.
Table 2
Sequences of oligonucleotide primers used for the semi-quantitativeRT-PCRampliﬁcation
of gp91phox cDNA
Gene Primers Sequence Position
β-actin 1 CCTCTGCCACCATGGGGAACT 294
2a GACTTCAAAGTAAGACCTCCGGATG 1131
gp91phox 3 ATCTGGCACCACACCTTCTACAATGAGCTGCG 2
4a CGTCATACTCCTGCTTGCTGATCCACATCTGC 624
a Anti-sense strand.
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case of patient II-2 (bottom panel), despite the low but measurable
NADPH oxidase activity in his granulocytes, as shown previously
(Figs. 2–4), gp91phox was not detected in the RCHT2− population
(97%) and only eosinophils (1.9%) were gp91phox-positive.
RT-PCR and sequence analysis were performed to localize the
mutation in the mRNA encoding gp91phox of patient II-2. mRNA was
reverse-transcribed into three overlapping cDNA fragments with
three pairs of oligonucleotide primers derived from the gp91phox
cDNA and were sequenced as described in Materials and methods. No
mutations in the cDNA of gp91phox protein were found. A portion of
the gp91phox promoter region in genomic DNA of CYBBwas ampliﬁed
by PCR [19]. Using sequence analysis, a thymidine insertionwas found
located between position −54T to −56T (Fig. 7A). This mutation is
located in a region between the “CCAAT” and the “TATA” boxes in a
consensus binding site for the ets family of transcription factors of the
gp91phox promoter responsible for CYBB transcription (Fig. 7B).
Genomic DNA from 50 control subjects was analyzed and no
mutations were found.
Then electrophoretic mobility shift assays were performed to
evaluate the impact of this new mutation of the CYBB promoter on
the speciﬁc binding with regulatory transcription factors of a nuclear
protein extract from PLB-985 cells. Fig. 8 shows that a DNA/protein
complex (indicated by the arrow) is formed when a labelled wild-
type double-strand oligonucleotide of the CYBB promoter region
(−68 to −30) is used as a probe. The DNA/protein binding is speciﬁc
as it is progressively inhibited by competition with a 20-, 50- and
100-fold molar excess of the unlabelled WT double-stranded
oligonucleotide probe. On the contrary, adding an increasing amountof X91− CGD unlabelled double-stranded oligonucleotide probe is
ineffective.
In order to study the impact of the defect of transcription factor
binding on the mutated CYBB promoter region, the amount of
gp91phox mRNA from patient II-2′s mononuclear cells was estimated
by semi-quantitative RT-PCR using β-actin, a housekeeping gene as an
internal standard. The PCR was performed with 20, 25, and 30 cycles
(data not shown). Finally, 25 cycles of PCR was chosen in order to be in
the exponential phase of the PCR ampliﬁcation and before reaching the
plateau for both testedmRNA. As shown in Fig. 9, a 624-bp fragment of
comparable intensity was obtained from the control, X91+ and X910
CGD patients' gp91phox mRNA. In contrast, patient II-2's gp91phox
mRNAampliﬁcationwas very lowwhile the signal of the housekeeping
gene was similar in all the tested mRNA. We also did the same
experimentwith total ARNpuriﬁed from the granulocyte population of
patient II-2 and we obtained the same results (data not shown).
To determine the impact of the residual NADPH oxidase activity of
neutrophils on microbicidal activity, in vitro killing assays were
performed using S. aureus, C. albicans and E. coli as targets. Fig. 10
Fig. 5. Reduced minus oxidized spectra and Western blot analysis of cytochrome b558 of neutrophils from the X CGD patients. The experiments were performed on 1% Triton X-100
soluble extract of neutrophils. (A) Reduced minus oxidized difference spectra of cytochrome b558 from neutrophils of a healthy donor, patient II-2 and an X910 CGD patient. (B)
Immunodetection of the α (p22phox) and β(gp91phox) subunits of cytochrome b558 neutrophils of patient II-2, an X910 CGD patient and a healthy donor. All samples were subjected
to SDS-PAGE and blotted onto a nitrocellulose sheet. Cytochrome b558α and β subunits were revealed withmonoclonal antibodies 449 (α subunit) and 48 (β subunit), as described in
Materials and methods. The results of one experiment representative of the two performed, with similar results, are reported.
Fig. 6. Surface expression of gp91phox on neutrophils and eosinophils. Granulocyte
preparations from a healthy subject (top panels) and from patient II-2 (bottom panels)
were stained with the anti gp91phox mAb 7D5 and the eosinophil speciﬁc anti-CRTH2
mAb (right panels), or a control mAb and CRTH2 (left panels). For experimental details,
see Materials and methods.
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was superimposable to that of neutrophils from an X910 CGD patient,
i.e. no killing of S. aureus and C. albicans, normal killing of E. coli. No
killing of both S. aureus and C. albicans could be observed even after
prolonging to 90 min the time of incubation (data not shown).
However the normal killing of E. Coli for both X910 and X91− CGD
highlights that it was NADPH oxidase independent.
4. Discussion
The majority of genetic lesions found in X91− CGD variants of
chronic granulomatous disease are missense mutations or small
deletions located in the encoding region of CYBB, whereas, up to now,
only four point mutations have been described in the CYBB promoter
region [17–19]. All these X91− CGD variants are characterized by a low
expression of cytochrome b558 and display some NADPH oxidase
activity.
We report here for the ﬁrst time the occurrence of an insertion in
the promoter of CYBB gene (T insertion between position −54 and
−56) leading to a rare variant of X91− CGD in an Italian family. On the
basis of the amount of superoxide anion produced and the NBT test it
was possible to demonstrate that neutrophils from the two members
affected, II-2 and III-5, retained some oxidase activity (Table 1 and
Figs. 2 and 3). Assay of hydrogen peroxide production by DHR 123
oxidation in neutrophils from patient II-2 showed a single peak of
ﬂuorescence, indicating that neutrophil population responded homo-
geneously to PMA with a respiratory burst. Such a response was only
about 6% of control (Fig. 3). The NADPH oxidase dependence of this
Fig. 7. Analysis of mutations in the CYBB gene from patient II-2. PCR products were gel-puriﬁed and automatically sequenced by Cogenics, Meylan, France, with forward and backward
primers P1 and P2⁎, as described in Materials and methods. (A) Thymidine insertion detected in the CYBB promoter region of patient II-2, compared to a healthy donor sequence. (B)
Schematic representation of part of the CYBB promoter region, with localization of the “CCAAT” and “TATA” boxes, the ATG starting codon and the pointmutation described in panel A.
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demonstrated by the complete sensitivity to inhibition by DPI (Figs. 2
and 3). A homogeneous weakly responsive neutrophil populationwas
also reported in other X91− CGD patients but no identiﬁcation of the
speciﬁc CYBB mutation has been done for these subjects [37,38]. The
eosinophils from patient II-2 strongly reduced NBT and oxidized DHR
(Figs. 2 and 4). In the neutrophil population from patient II-2 (which is
RCTH2−), cytochrome b558 could not be detected, probably because
the amount of gp91phox expressed at the surface of each cell is low
and is under the ﬂow cytometry's sensitivity limit (Fig. 6). However,
the low percentage of eosinophils in patient II-2 (about 2% of the
granulocyte population) cannot explain the homogeneous weakly but
DPI inhibited respiratory burst measured in the PMA-activated
neutrophil population (Figs. 3 and 4).Fig. 8. Electrophoretic mobility shift assay. Gel shift analysis was performed as
described in Materials and methods using the −68- to −30-bp region of the wild-type
(WT) CYBB promoter as biotin labelled probe. The WT-labelled probe was incubated
with 10 μg of nuclear extract from undifferentiated PLB 985 cells after preincubation
with 20-, 50-, or 100-fold molar excess of unlabelled double-stranded WT or X91− CGD
competitor oligonucleotide as indicated. The data are representative of three separate
experiments.A small population (5% to 15%) of granulocytes with completely
normal respiratory burst activity has beenpreviously found inX91− CGD
patients (T-55C mutation in the promoter region of CYBB [17]. In two
other X91− CGD cases caused by point mutations in the same CYBB
promoter region (C-52T, C-53T), a small population of NBT-positive cells
was described that turned out to be eosinophils [18]. The presence of
oxidase positive eosinophils in these patients may be explained by the
demonstration that gp91phox expression in eosinophils is regulated by
speciﬁc transcription factors (GATA1 and GATA2) different from those
operative in neutrophils monocytes and B-lymphocytic cells [39].
The new insertion mutation described here (Fig. 7) is located
between the “CCAAT” and “TATA” box in a consensus binding
sequence for the ets family of transcription factors of the gp91phox
promoter site (5′-GAGGAAAT-3′, lower strand, −57 to −50 bp), that are
involved in eukaryotic gene transcription [40]. Mutations in this
region are known to be related to the loss of association of DNA-
binding proteins (Elf-1 and PU.1) and to prevent the full expression of
the CYBB gene in neutrophils and monocytes [17,41,42]. Indeed, using
EMSAwe demonstrated a DNA–protein binding complex formation of
nuclear extract from PLB-985 cells with the biotin-labelled wild-type
double-strand oligonucleotide of the CYBB promoter region (−68 to
−30). The speciﬁcity of the binding was demonstrated because an
increasing amount of unlabelled WT oligonucleotide probe decreased
the DNA–protein binding complex formation while the mutated X91−
oligonucleotide probe was ineffective (Fig. 8). The consequence of this
transcription factor binding defect was a reduced gp91phox mRNA
expression in mononuclear cells or granulocytes (Fig. 9) correlated
with a diminished cytochrome b558 expression in patient II-2's
neutrophil population (Table 1 and Fig. 5). The diminished expression
of gp91phox in patients II-2 and patient III-5 correlates with the low
respiratory burst of their neutrophils. The ﬁnding that the eosinophils
of our patients were oxidase positive is in keeping with the above
mentioned observation that expression of gp91phox in eosinophils is
regulated by transcription factors different from those active on
neutrophils [39]. On the whole, the phenotypic proﬁle of these cells is
very similar to that of other X91− CGD neutrophils with point
mutations in the CYBB promoter (C-52T, C-53T, T-55C, A-57T) [17–19].
In order to understand the role of the residual NADPH oxidase
activity in the microbicidal activity of X91− CGD neutrophils, killing of
Fig. 9. Semi-quantitative RT-PCR ampliﬁcation of gp91phox mRNA from patient II-2. The gp91phox mRNA from patient II-2, X91+ and X910 CGD patients and from a healthy subject
were ampliﬁed by RT-PCR using primers 1 and 2⁎ (see Table 2 for sequences and positions). The housekeeping gene of β-actin was used as internal control. M, DNA size markers. The
data are representative of three separate experiments.
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fungus (C. albicans) by patient II-2 neutrophils were assessed and
comparedwith killing by X910 CGD neutrophils (Fig.10). As previously
shown [28], neutrophils from the X910 CGD patient were unable to kill
both S. aureus and C. albicans and killed normally E. coli. The results
obtained with patient II-2 neutrophils indicate that the residual
NADPH oxidase activity of patient II-2 neutrophils (5–7% of control) is
not sufﬁcient to guarantee any killing of S. aureus and C. albicans in
vitro, even after long incubation times (90 min, data not shown).
Bactericidal activity of X91− CGD neutrophils was performed in only
few studies [11,37]. The killing of S. aureus by X91− CGD neutrophils in
these studies was found only partially defective and comparable to
that of X910 CGD neutrophils. The discrepancy of these data with ours
can be explained by the fact that techniques commonly used to assess
bacterial killing were affected by a methodological ﬂaw that under-
mined reliability of the results obtained [28]. In an additional study
[18] a defective killing of E. coli by X91− CGD neutrophils was
demonstrated. In that study, killing of E. coli (strain ML35) was
measured by following the kinetics of perforation of the bacterial cell
envelope [43]. E. coli appear to be efﬁciently killed by non-oxidative
mechanisms ([28,44] and data presented in this study). Therefore we
have no explanation for the differences in killing between ref.18 and
our results, considering that perforation assay of killing and the
classical killing assay (CFU) were shown to give comparable results
[43]. It is likely that the microbicidal defect demonstrated using the
perforation technique does not reﬂect changes in the number of viable
bacteria detected as colony forming units or that the observed
differences depend on the different strains of E. coli used.
The strongly defective killing of S. aureus and C. albicans which are
preferential pathogens found in CGD, in spite of the low O2− productionFig. 10. Microbicidal activity of neutrophils from X CGD patients. Neutrophils from a
control subject, patient II-2 and a patient with X910 CGD were incubated with
opsonized S. aureus at MOI 3–5:1, C. albicans at MOI 1–2:1 and E. coli at MOI 3–5:1. Data
are expressed as percent killing after 45 min incubation for S. aureus and E. coli, and
after 60 min incubation for C. albicans. The results are means of 3–4 experiments for
patient II-2 and 2–3 experiments for the X910 CGD patient. For experimental details, see
Materials and methods.maywell explain the clinical conditions of patients II-2 and III-5, both of
which suffered from recurrent and severe infections requiring
hospitalization and patient III-5 died from pneumonia at the age of 20
when the diagnosis of CGDwasmade. It is the case for some previously
described X91− CGD patients with the same type of CYBB promoter's
mutations [17,45]. However the frequencyand the severity of infections
among the X91− CGD variant patients characterized by point mutation
in the same CYBB promoter region, vary considerably. Reasons for
discrepancies between the infectious complications and the respiratory
burst capabilities in such patients are unclear. However a mild clinical
expression in these X91− CGD variant patients can be explained by a
high level of eosinophils (N10%) normally expressingNADPH oxidase in
the blood [18]. Yet the compensation mechanism of eosinophil over-
production is not known.Mothers who are carriers of the classical X910
CGD are generally protected against severe infections even in cases of
extreme lyonization, with b15% of neutrophils with a normal
respiratory burst [46]. This indicates that even a low percentage of
neutrophilswith a normal respiratory burst is enough to protect against
infections. In our study, neutrophils from patients II-2 and III-5
produced reactive oxygen species at a rate corresponding to 5–7% of
control. This response, however, is “diluted” among the whole cell
population. Evidently, such a low level of oxidativemetabolism, ona per
cell basis, is not sufﬁcient to allowmicrobial killing and to protect from
infections. These observations raise questions about the levels of
respiratory burst activity required for microbial killing and studies on
this line are now underway using myeloid lines transfected with NOX
mutants exhibiting various levels of oxidative activity.
Systematic characterization of gene mutations in CGD patients is
essential for genetic counseling and prenatal diagnosis. It would be
also of help in relating the clinical form of the disease to the type of
gene affected and/or the type of mutation found. However, we believe
that the number of X91− CGD variant cases with a well-documented
clinical history and a deﬁned genetic lesion described up-to-now is
not sufﬁcient to provide a clear and deﬁnitive correlation between
mutation and severity of the clinical course.
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